In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.

which is crucial for understanding drug mechanisms and optimizing treatment strategies. Overall, the landscape of cell viability assays is evolving, with ongoing research aimed at improving ...

MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

Global Cell-Based Assays Market size is expected to be worth around US$ 37.1 Billion by 2032 from US$ 17.7 Billion in 2023, growing at a CAGR of 8.8% ...